Loading…
Development of Antimicrobial Defined Daily Dose (DDD) for the Pediatric Population
Antimicrobial stewardship programs (ASPs) optimize antimicrobial use, improve patient outcomes, and reduce resistance. To assess the effectiveness of ASPs, it is necessary to have indicators that can be widely used. Defined daily dose (DDD) was designed by WHO for the adult population as a consumpti...
Saved in:
Published in: | Antibiotics (Basel) 2023-01, Vol.12 (2), p.276 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c566t-c36e46604f464ae6b80c169312e80c60c142f958aeba7a6acc4a1034f71b1fff3 |
---|---|
cites | cdi_FETCH-LOGICAL-c566t-c36e46604f464ae6b80c169312e80c60c142f958aeba7a6acc4a1034f71b1fff3 |
container_end_page | |
container_issue | 2 |
container_start_page | 276 |
container_title | Antibiotics (Basel) |
container_volume | 12 |
creator | Montecatine-Alonso, Elena Mejías-Trueba, Marta Goycochea-Valdivia, Walter Alfredo Chavarri-Gil, Estibaliz Fernández-Llamazares, Cecilia M Dolz, Elisenda Gutiérrez-Urbón, José María Gallego-Fernández, Carmen Llorente-Gutiérrez, Jesús Gil-Navarro, María Victoria |
description | Antimicrobial stewardship programs (ASPs) optimize antimicrobial use, improve patient outcomes, and reduce resistance. To assess the effectiveness of ASPs, it is necessary to have indicators that can be widely used. Defined daily dose (DDD) was designed by WHO for the adult population as a consumption indicator. However, there are no DDDs adapted to the pediatric population. The main objective of this study is to establish the most appropriate DDD values in this population. An observational, retrospective, multicenter study was conducted. Antimicrobial prescriptions were collected from pediatric wards of seven Spanish tertiary hospitals for 2 years. The DDDs obtained from the prescriptions were compared with the theoretical DDDs agreed upon in the first stage. To select the optimal DDD, the following were analyzed: power value, magnitude obtained from the differences in the DDD, statistical significance, and degree of agreement in the stipulated doses. A total of 4788 prescriptions were collected. Pediatric DDD was defined for 30 different antimicrobials. A potency >80% was obtained in 24 antibiotics. 51.2% of the selected DDD correspond to Phase I and 39.5% from Phase II. Pediatric DDD of different antimicrobials was obtained, providing an indicator that can be used globally in different hospitals to analyze the consumption and efficacy of ASPs. |
doi_str_mv | 10.3390/antibiotics12020276 |
format | article |
fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_b37a871f7611468dabb6e577b2f1a92c</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A742992850</galeid><doaj_id>oai_doaj_org_article_b37a871f7611468dabb6e577b2f1a92c</doaj_id><sourcerecordid>A742992850</sourcerecordid><originalsourceid>FETCH-LOGICAL-c566t-c36e46604f464ae6b80c169312e80c60c142f958aeba7a6acc4a1034f71b1fff3</originalsourceid><addsrcrecordid>eNptUk1r3DAQNaWlCWl-QaEYekkPm-rD1selsMRtEwg0lPYsxvJoo8W2trI3kH_fSTcJuyWag0bSe0_MmymK95ydS2nZZxjn2MY0Rz9xwSi0elUcC6btQkkjXu_lR8XpNK0ZLculYeZtcSSVkYwbfVz8bPAO-7QZcJzLFMol6Q7R59RG6MsGQxyxKxuI_X3ZpAnLs6ZpPpUh5XK-xfIGuwhzjr68SZttD3NM47viTYB-wtPH_aT4_e3rr4vLxfWP71cXy-uFr5WaF14qrJRiVahUBahawzxXVnKBlCk6VCLY2gC2oEGB9xVwJqugectDCPKkuNrpdgnWbpPjAPneJYju30XKKweZDOrRtVKD0TxoxXmlTAdtq7DWuhWBgxWetL7stDbbdsDOkxsZ-gPRw5cx3rpVunPW1kJJSwJnjwI5_dniNLshTh77HkZM28kJbRjTqjaSoB__g67TNo9kFaG0rVmlxB5qBVRAHEOif_2DqFvqSlgrTM0Idf4CiqJD6mIaqX90f0CQOwK1eJoyhucaOXMPk-VemCxifdi355nzNEfyL6udyjg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2779504623</pqid></control><display><type>article</type><title>Development of Antimicrobial Defined Daily Dose (DDD) for the Pediatric Population</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Montecatine-Alonso, Elena ; Mejías-Trueba, Marta ; Goycochea-Valdivia, Walter Alfredo ; Chavarri-Gil, Estibaliz ; Fernández-Llamazares, Cecilia M ; Dolz, Elisenda ; Gutiérrez-Urbón, José María ; Gallego-Fernández, Carmen ; Llorente-Gutiérrez, Jesús ; Gil-Navarro, María Victoria</creator><creatorcontrib>Montecatine-Alonso, Elena ; Mejías-Trueba, Marta ; Goycochea-Valdivia, Walter Alfredo ; Chavarri-Gil, Estibaliz ; Fernández-Llamazares, Cecilia M ; Dolz, Elisenda ; Gutiérrez-Urbón, José María ; Gallego-Fernández, Carmen ; Llorente-Gutiérrez, Jesús ; Gil-Navarro, María Victoria</creatorcontrib><description>Antimicrobial stewardship programs (ASPs) optimize antimicrobial use, improve patient outcomes, and reduce resistance. To assess the effectiveness of ASPs, it is necessary to have indicators that can be widely used. Defined daily dose (DDD) was designed by WHO for the adult population as a consumption indicator. However, there are no DDDs adapted to the pediatric population. The main objective of this study is to establish the most appropriate DDD values in this population. An observational, retrospective, multicenter study was conducted. Antimicrobial prescriptions were collected from pediatric wards of seven Spanish tertiary hospitals for 2 years. The DDDs obtained from the prescriptions were compared with the theoretical DDDs agreed upon in the first stage. To select the optimal DDD, the following were analyzed: power value, magnitude obtained from the differences in the DDD, statistical significance, and degree of agreement in the stipulated doses. A total of 4788 prescriptions were collected. Pediatric DDD was defined for 30 different antimicrobials. A potency >80% was obtained in 24 antibiotics. 51.2% of the selected DDD correspond to Phase I and 39.5% from Phase II. Pediatric DDD of different antimicrobials was obtained, providing an indicator that can be used globally in different hospitals to analyze the consumption and efficacy of ASPs.</description><identifier>ISSN: 2079-6382</identifier><identifier>EISSN: 2079-6382</identifier><identifier>DOI: 10.3390/antibiotics12020276</identifier><identifier>PMID: 36830187</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Age ; Antibiotics ; Antiinfectives and antibacterials ; Antimicrobial agents ; antimicrobial stewardship program ; antimicrobials ; Computerized physician order entry ; Computers ; Consumption ; Consumption (Economics) ; Data collection ; defined daily dose (DDD) ; Delphi method ; Drug resistance ; Hospitals ; Indicators ; Metronidazole ; Normal distribution ; Optimization ; pediatric ; Pediatrics ; Penicillin G ; Population ; Prescriptions ; Services</subject><ispartof>Antibiotics (Basel), 2023-01, Vol.12 (2), p.276</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c566t-c36e46604f464ae6b80c169312e80c60c142f958aeba7a6acc4a1034f71b1fff3</citedby><cites>FETCH-LOGICAL-c566t-c36e46604f464ae6b80c169312e80c60c142f958aeba7a6acc4a1034f71b1fff3</cites><orcidid>0000-0003-3819-4966 ; 0000-0002-7074-3016</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2779504623/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2779504623?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36830187$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Montecatine-Alonso, Elena</creatorcontrib><creatorcontrib>Mejías-Trueba, Marta</creatorcontrib><creatorcontrib>Goycochea-Valdivia, Walter Alfredo</creatorcontrib><creatorcontrib>Chavarri-Gil, Estibaliz</creatorcontrib><creatorcontrib>Fernández-Llamazares, Cecilia M</creatorcontrib><creatorcontrib>Dolz, Elisenda</creatorcontrib><creatorcontrib>Gutiérrez-Urbón, José María</creatorcontrib><creatorcontrib>Gallego-Fernández, Carmen</creatorcontrib><creatorcontrib>Llorente-Gutiérrez, Jesús</creatorcontrib><creatorcontrib>Gil-Navarro, María Victoria</creatorcontrib><title>Development of Antimicrobial Defined Daily Dose (DDD) for the Pediatric Population</title><title>Antibiotics (Basel)</title><addtitle>Antibiotics (Basel)</addtitle><description>Antimicrobial stewardship programs (ASPs) optimize antimicrobial use, improve patient outcomes, and reduce resistance. To assess the effectiveness of ASPs, it is necessary to have indicators that can be widely used. Defined daily dose (DDD) was designed by WHO for the adult population as a consumption indicator. However, there are no DDDs adapted to the pediatric population. The main objective of this study is to establish the most appropriate DDD values in this population. An observational, retrospective, multicenter study was conducted. Antimicrobial prescriptions were collected from pediatric wards of seven Spanish tertiary hospitals for 2 years. The DDDs obtained from the prescriptions were compared with the theoretical DDDs agreed upon in the first stage. To select the optimal DDD, the following were analyzed: power value, magnitude obtained from the differences in the DDD, statistical significance, and degree of agreement in the stipulated doses. A total of 4788 prescriptions were collected. Pediatric DDD was defined for 30 different antimicrobials. A potency >80% was obtained in 24 antibiotics. 51.2% of the selected DDD correspond to Phase I and 39.5% from Phase II. Pediatric DDD of different antimicrobials was obtained, providing an indicator that can be used globally in different hospitals to analyze the consumption and efficacy of ASPs.</description><subject>Age</subject><subject>Antibiotics</subject><subject>Antiinfectives and antibacterials</subject><subject>Antimicrobial agents</subject><subject>antimicrobial stewardship program</subject><subject>antimicrobials</subject><subject>Computerized physician order entry</subject><subject>Computers</subject><subject>Consumption</subject><subject>Consumption (Economics)</subject><subject>Data collection</subject><subject>defined daily dose (DDD)</subject><subject>Delphi method</subject><subject>Drug resistance</subject><subject>Hospitals</subject><subject>Indicators</subject><subject>Metronidazole</subject><subject>Normal distribution</subject><subject>Optimization</subject><subject>pediatric</subject><subject>Pediatrics</subject><subject>Penicillin G</subject><subject>Population</subject><subject>Prescriptions</subject><subject>Services</subject><issn>2079-6382</issn><issn>2079-6382</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptUk1r3DAQNaWlCWl-QaEYekkPm-rD1selsMRtEwg0lPYsxvJoo8W2trI3kH_fSTcJuyWag0bSe0_MmymK95ydS2nZZxjn2MY0Rz9xwSi0elUcC6btQkkjXu_lR8XpNK0ZLculYeZtcSSVkYwbfVz8bPAO-7QZcJzLFMol6Q7R59RG6MsGQxyxKxuI_X3ZpAnLs6ZpPpUh5XK-xfIGuwhzjr68SZttD3NM47viTYB-wtPH_aT4_e3rr4vLxfWP71cXy-uFr5WaF14qrJRiVahUBahawzxXVnKBlCk6VCLY2gC2oEGB9xVwJqugectDCPKkuNrpdgnWbpPjAPneJYju30XKKweZDOrRtVKD0TxoxXmlTAdtq7DWuhWBgxWetL7stDbbdsDOkxsZ-gPRw5cx3rpVunPW1kJJSwJnjwI5_dniNLshTh77HkZM28kJbRjTqjaSoB__g67TNo9kFaG0rVmlxB5qBVRAHEOif_2DqFvqSlgrTM0Idf4CiqJD6mIaqX90f0CQOwK1eJoyhucaOXMPk-VemCxifdi355nzNEfyL6udyjg</recordid><startdate>20230131</startdate><enddate>20230131</enddate><creator>Montecatine-Alonso, Elena</creator><creator>Mejías-Trueba, Marta</creator><creator>Goycochea-Valdivia, Walter Alfredo</creator><creator>Chavarri-Gil, Estibaliz</creator><creator>Fernández-Llamazares, Cecilia M</creator><creator>Dolz, Elisenda</creator><creator>Gutiérrez-Urbón, José María</creator><creator>Gallego-Fernández, Carmen</creator><creator>Llorente-Gutiérrez, Jesús</creator><creator>Gil-Navarro, María Victoria</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T7</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-3819-4966</orcidid><orcidid>https://orcid.org/0000-0002-7074-3016</orcidid></search><sort><creationdate>20230131</creationdate><title>Development of Antimicrobial Defined Daily Dose (DDD) for the Pediatric Population</title><author>Montecatine-Alonso, Elena ; Mejías-Trueba, Marta ; Goycochea-Valdivia, Walter Alfredo ; Chavarri-Gil, Estibaliz ; Fernández-Llamazares, Cecilia M ; Dolz, Elisenda ; Gutiérrez-Urbón, José María ; Gallego-Fernández, Carmen ; Llorente-Gutiérrez, Jesús ; Gil-Navarro, María Victoria</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c566t-c36e46604f464ae6b80c169312e80c60c142f958aeba7a6acc4a1034f71b1fff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Age</topic><topic>Antibiotics</topic><topic>Antiinfectives and antibacterials</topic><topic>Antimicrobial agents</topic><topic>antimicrobial stewardship program</topic><topic>antimicrobials</topic><topic>Computerized physician order entry</topic><topic>Computers</topic><topic>Consumption</topic><topic>Consumption (Economics)</topic><topic>Data collection</topic><topic>defined daily dose (DDD)</topic><topic>Delphi method</topic><topic>Drug resistance</topic><topic>Hospitals</topic><topic>Indicators</topic><topic>Metronidazole</topic><topic>Normal distribution</topic><topic>Optimization</topic><topic>pediatric</topic><topic>Pediatrics</topic><topic>Penicillin G</topic><topic>Population</topic><topic>Prescriptions</topic><topic>Services</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Montecatine-Alonso, Elena</creatorcontrib><creatorcontrib>Mejías-Trueba, Marta</creatorcontrib><creatorcontrib>Goycochea-Valdivia, Walter Alfredo</creatorcontrib><creatorcontrib>Chavarri-Gil, Estibaliz</creatorcontrib><creatorcontrib>Fernández-Llamazares, Cecilia M</creatorcontrib><creatorcontrib>Dolz, Elisenda</creatorcontrib><creatorcontrib>Gutiérrez-Urbón, José María</creatorcontrib><creatorcontrib>Gallego-Fernández, Carmen</creatorcontrib><creatorcontrib>Llorente-Gutiérrez, Jesús</creatorcontrib><creatorcontrib>Gil-Navarro, María Victoria</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Antibiotics (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Montecatine-Alonso, Elena</au><au>Mejías-Trueba, Marta</au><au>Goycochea-Valdivia, Walter Alfredo</au><au>Chavarri-Gil, Estibaliz</au><au>Fernández-Llamazares, Cecilia M</au><au>Dolz, Elisenda</au><au>Gutiérrez-Urbón, José María</au><au>Gallego-Fernández, Carmen</au><au>Llorente-Gutiérrez, Jesús</au><au>Gil-Navarro, María Victoria</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of Antimicrobial Defined Daily Dose (DDD) for the Pediatric Population</atitle><jtitle>Antibiotics (Basel)</jtitle><addtitle>Antibiotics (Basel)</addtitle><date>2023-01-31</date><risdate>2023</risdate><volume>12</volume><issue>2</issue><spage>276</spage><pages>276-</pages><issn>2079-6382</issn><eissn>2079-6382</eissn><abstract>Antimicrobial stewardship programs (ASPs) optimize antimicrobial use, improve patient outcomes, and reduce resistance. To assess the effectiveness of ASPs, it is necessary to have indicators that can be widely used. Defined daily dose (DDD) was designed by WHO for the adult population as a consumption indicator. However, there are no DDDs adapted to the pediatric population. The main objective of this study is to establish the most appropriate DDD values in this population. An observational, retrospective, multicenter study was conducted. Antimicrobial prescriptions were collected from pediatric wards of seven Spanish tertiary hospitals for 2 years. The DDDs obtained from the prescriptions were compared with the theoretical DDDs agreed upon in the first stage. To select the optimal DDD, the following were analyzed: power value, magnitude obtained from the differences in the DDD, statistical significance, and degree of agreement in the stipulated doses. A total of 4788 prescriptions were collected. Pediatric DDD was defined for 30 different antimicrobials. A potency >80% was obtained in 24 antibiotics. 51.2% of the selected DDD correspond to Phase I and 39.5% from Phase II. Pediatric DDD of different antimicrobials was obtained, providing an indicator that can be used globally in different hospitals to analyze the consumption and efficacy of ASPs.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>36830187</pmid><doi>10.3390/antibiotics12020276</doi><orcidid>https://orcid.org/0000-0003-3819-4966</orcidid><orcidid>https://orcid.org/0000-0002-7074-3016</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2079-6382 |
ispartof | Antibiotics (Basel), 2023-01, Vol.12 (2), p.276 |
issn | 2079-6382 2079-6382 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_b37a871f7611468dabb6e577b2f1a92c |
source | Publicly Available Content Database; PubMed Central |
subjects | Age Antibiotics Antiinfectives and antibacterials Antimicrobial agents antimicrobial stewardship program antimicrobials Computerized physician order entry Computers Consumption Consumption (Economics) Data collection defined daily dose (DDD) Delphi method Drug resistance Hospitals Indicators Metronidazole Normal distribution Optimization pediatric Pediatrics Penicillin G Population Prescriptions Services |
title | Development of Antimicrobial Defined Daily Dose (DDD) for the Pediatric Population |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T14%3A41%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20Antimicrobial%20Defined%20Daily%20Dose%20(DDD)%20for%20the%20Pediatric%20Population&rft.jtitle=Antibiotics%20(Basel)&rft.au=Montecatine-Alonso,%20Elena&rft.date=2023-01-31&rft.volume=12&rft.issue=2&rft.spage=276&rft.pages=276-&rft.issn=2079-6382&rft.eissn=2079-6382&rft_id=info:doi/10.3390/antibiotics12020276&rft_dat=%3Cgale_doaj_%3EA742992850%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c566t-c36e46604f464ae6b80c169312e80c60c142f958aeba7a6acc4a1034f71b1fff3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2779504623&rft_id=info:pmid/36830187&rft_galeid=A742992850&rfr_iscdi=true |